Mount Dora, Florida 32757

  • Astigmatism


This is a prospective, multicenter, post-approval active surveillance study. The purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an ACRYSOF IQ RESTOR Toric or ACRYSOF IQ RESTOR IOL in the US.

Study summary:

If a second eye will participate in the study, subjects will receive the second eye cataract surgery within 60 days of the screening Visit 0. Four postoperative follow-up visits are planned to occur at 1-2 days, 7-14 days, 30-60 days, and 90-180 days, for each enrolled eye. Subject participation in this study is expected to last up to 7 months, including a total of 6 study visits for subjects implanted in one eye and up to 11 visits for subjects implanted in both eyes. Upon completion of the 180 days follow-up visit, subjects will be exited from the study.


Inclusion Criteria: - Preoperative cataract in the study eye(s) - Planned implantation in at least one eye with: - Cohort 1: An ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL (Models SND1T3, SND1T4, SND1T5 or SND1T6) or an ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOLs (Models SV25T3, SV25T4, SV25T5, and SV25T6) in accordance with the product labeling from November 2018 to July 2020 - Cohort 2: An ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL (Models SND1T3, SND1T4, SND1T5 or SND1T6), or an ACRYSOF IQ RESTOR +2.5 D Multifocal IOL (Model SV25T0) in accordance with the product labeling after July 2020. - Able to comprehend and sign a statement of informed consent - Willing and able to complete all required postoperative visits - Other protocol-specified inclusion criteria may apply. Exclusion Criteria: - Eyes with clinically significant ocular, including adnexa, or intraocular infection or inflammation (at the screening visit prior to surgery or on the day of surgery) - History of any intraocular inflammation within the past 12 months (ex: uveitis, choroiditis) - Combined procedures introducing an additional medical device during cataract surgery (ex: cataract surgery with implant of glaucoma stent) - Other protocol-specified exclusion criteria may apply.



Primary Contact:

Study Director
Sr. Clinical Trial Lead, CDMA Surgical
Alcon Research

Alcon Call Center
Phone: 1-888-451-3937

Backup Contact:


Location Contact:

Mount Dora, Florida 32757
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: September 26, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.